Related Experiment Video
Updated: Jan 28, 2026

A Guide to Generating and Using hiPSC Derived NPCs for the Study of Neurological Diseases
Published on: February 21, 2015
Disease comorbidity-guided drug repositioning: a case study in schizophrenia
1Department of Population and Quantitative Health Sciences, School of Medicine, Case Western Reserve University, Cleveland OH 44106.
None:
The key to any computational drug repositioning is the availability of relevant data in machine-understandable format. While large amount of genetic, genomic and chemical data are publicly available, large-scale higher-level disease and drug phenotypic data are limited. We recently constructed a large-scale disease-comorbidity relationship knowledge base (dCombKB) and a comprehensive drug-treatment relationship knowledge base (TreatKB) from 21 million biomedical research articles and other resources. In this study, we demonstrated the potential of dCombKB and TreatKB in drug repositioning for schizophrenia, one of the top ten illnesses contributing to the global burden of disease. dCombKB contains 121,359 unique disease-disease comorbidity pairs for 23,041 diseases. TreatKB contains 208,330 unique drug-disease treatment pairs for 2,484 drugs and 24,511 diseases. We constructed a phenotypic comorbidity disease network (PDN) of 14,645 disease nodes and 101,275 edges based on dCombKB. We applied standard network-based ranking algorithm to find diseases that are phenotypically related to SCZ. We developed a drug prioritization system, PhenoPredict-CDN, to systematically reposition drugs for SCZ from diseases phenotypically related to SCZ. PhenoPredict-CDN found all 18 FDA-approved SCZ drugs and ranked them highly as tested in a de-novo validation setting (recall: 1.0, mean ranking: top 6.05%, median ranking: top 1.65%). When compared to PREDICT, a comprehensive drug repositioning system, for novel predictions, Pheno-Predict-CDN outperformed PREDICT in Precision-Recall (PR) curves across three different evaluation datasets. Compared to PREDICT, PhenoPredict-CDN showed a significant 110.0-230.0% improvements in mean average precision. In summary, large-scale higher-level disease-comorbidity relationships data extracted from biomedical literature has potential in drug discovery for SCZ, a complex disease with unknown pathophysiological mechanisms. All the data are publicly available: dCombKB at http://nlp.
Case:
edu/public/data/dCombKB, TreatKB at http://nlp.
Case:
edu/public/data/treatKB/, and predictions for SCZ at http://nlp.
Case:
edu/public/data/SCZ_CDN/.
Related Concept Videos
Schizophrenia
Biological Causes of Schizophrenia
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
Psychological and Sociocultural Causes of Schizophrenia
Negative and Cognitive Symptoms of Schizophrenia
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

